Central Precocious Puberty LAI

About Tolmar

Tolmar is a private, commercial-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of long-acting injectable drugs. Founded in 2002, it has built a portfolio of approved products sold in over 89 countries, primarily in therapeutic areas like prostate cancer, central precocious puberty, and testosterone replacement therapy. The company operates with a fully integrated model, controlling R&D, manufacturing in Colorado, and sales, which allows for a direct path to market and reliable supply. With over 1,100 employees, Tolmar leverages over 30 years of experience in long-acting injectables to differentiate itself and pursue partnerships for further growth.

Therapeutic Areas